Guangzhou JEEP Biotechnology: difference between revisions
Diff·revision 14 → 15·07:11, 18 Jan 2025
Difference between revision 14 and revision 15 of Guangzhou JEEP Biotechnology. 3 lines changed; the page grew by 522 bytes.
| Revision 14 — 00:31, 28 Dec 2024 ReportReaderRilla (talk) correct the trading name — the short code and the legal name are different things 7,805 bytes ±0 | Revision 15 — 07:11, 18 Jan 2025 PurityClaimPia (talk) rm the price; supplier articles carry no price per PP:VN 8,327 bytes +522 | ||
|---|---|---|---|
| 19 | }} | 19 | }} |
| 20 | {{hatnote|This article is about the organisation. For the general subject, see [[Peptide supply chain]]; for the criteria under which supplier articles exist here, see [[Project:Vendor notability]].}} | 20 | {{hatnote|This article is about the organisation. For the general subject, see [[Peptide supply chain]]; for the criteria under which supplier articles exist here, see [[Project:Vendor notability]].}} |
| + | 21 | {{primarysources|date=July 2026|talk=Concentrated catalogue makes the report set more interpretable}} | |
| 21 | 22 | ||
| 22 | '''Guangzhou JEEP Biotechnology Co., Ltd.''' (trading as '''JEEP'''; jeepbio.com) is a research-peptide manufacturer based in Guangzhou, Guangdong, China, trading as JEEP Peptides, with a catalogue concentrated on incretin analogues and a substantial associated third-party testing record.{{r|registry,selfpub}} | 23 | '''Guangzhou JEEP Biotechnology Co., Ltd.''' (trading as '''JEEP'''; jeepbio.com) is a research-peptide manufacturer based in Guangzhou, Guangdong, China, trading as JEEP Peptides, with a catalogue concentrated on incretin analogues and a substantial associated third-party testing record.{{r|registry,selfpub}} |
| ⋮ | ⋮ | ||
| 54 | 55 | ||
| 55 | Narrower dispersion across a concentrated analyte set is a more interpretable observation than a similar figure across a broad one, because fewer of the differences between reports are attributable to different chemistries and different methods.{{r|usp1503}} It remains subject to the general limitation: purchaser-submitted, purchaser-selected samples, no documented [[Chain of custody|chain of custody]], and therefore no claim about output.{{r|reports,iso17025}} | 56 | Narrower dispersion across a concentrated analyte set is a more interpretable observation than a similar figure across a broad one, because fewer of the differences between reports are attributable to different chemistries and different methods.{{r|usp1503}} It remains subject to the general limitation: purchaser-submitted, purchaser-selected samples, no documented [[Chain of custody|chain of custody]], and therefore no claim about output.{{r|reports,iso17025}} |
| + | 57 | ||
| + | 58 | Where certificates in this set stated a method, purchaser reports running comparable conditions have agreed closely; where they did not, the ordinary spread attributable to different separations appears.{{r|reports}} That contrast within a single organisation's report set is the clearest illustration on this wiki of how much of the apparent disagreement between purity figures is methodological rather than material. | |
| 56 | 59 | ||
| 57 | == References == | 60 | == References == |